There is lack of data about patient characteristics, practice patterns, and long-term adverse outcomes in patients with atrial fibrillation (AF) attending emergency departments (EDs) in China. A total of 2016 patients from 20 representative EDs were included. During 1 year, all-cause mortality was 291 (14.6%) cases, stroke/noncentral nervous system systemic embolism rate was 159 (8.0%) cases, and major bleeding was 26 (1.3%) cases. Heart failure, the major cause of mortality, accounted for 43.0% of deaths. Of 375 (18.6%) patients who used warfarin at baseline, only 217 (57.9%) patients were still on anticoagulation therapy during 1-year follow-up. Compared with the patients who continued on warfarin, the mortality rate was higher in those who did not continue (15.9% vs 5.5%, P < .001). Patients seen in ED with AF appear to have a high incidence rate of long-term all-cause mortality and inadequate anticoagulation rate.
CammAJKirchhofPLipGY. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the european society of cardiology (esc). Eur Heart J. 2010;31
(19):2369–2429.
CairnsJAConnollySMcMurtrySStephensonMTalajicM. Canadian cardiovascular society atrial fibrillation guidelines 2010: Prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27
(1):74–90.
4.
WalkeyAJWienerRSGhobrialJMCurtisLHBenjaminEJ. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA. 2011;306
(20):2248–2254.
5.
Le HeuzeyJY. Antithrombotic treatment of atrial fibrillation: new insights. Thromb Res. 2012;130
(suppl 1):S59–S60.
6.
HartRGBenaventeOMcBrideRPearceLA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131
(7):492–501.
7.
GotoSIkedaYShimadaK. One-year cardiovascular event rates in japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. -results from the japan thrombosis registry for atrial fibrillation, coronary, or cerebrovascular events (j-trace). Circ J. 2011;75(11):2598–2604
8.
LinLYLeeCHYuCC. Risk factors and incidence of ischemic stroke in taiwanese with nonvalvular atrial fibrillation-- a nation wide database analysis. Atherosclerosis. 2011;217
(1):292–295.
9.
KoganAShapiraRTamirARennertG. Antithrombotic therapy for prevention of stroke in clinical practice in the ed. Am J Emerg Med. 2007;25
(1):1–5.
10.
McDonaldAJPelletierAJEllinorPTCamargoCAJr. Increasing us emergency department visit rates and subsequent hospital admissions for atrial fibrillation from 1993 to 2004. Ann Emerg Med. 2008;51
(1):58–65.
11.
AtzemaCLAustinPCChongASDorianP. Factors associated with 90-day death after emergency department discharge for atrial fibrillation. Ann Emerg Med. 2013;61(5):539–548. e531.
12.
BenjaminEJWolfPAD'AgostinoRBSilbershatzHKannelWBLevyD. Impact of atrial fibrillation on the risk of death: The framingham heart study. Circulation. 1998;98
(10):946–952.
13.
ScheuermeyerFXGrafsteinEStenstromR. Thirty-day and 1-year outcomes of emergency department patients with atrial fibrillation and no acute underlying medical cause. Ann Emerg Med. 2012;60(6):755–765. e752.
14.
AtzemaCLLamKYoungCKester-GreeneN. Patients with atrial fibrillation and an alternative primary diagnosis in the emergency department: a description of their characteristics and outcomes. Acad Emerg Med. 2013;20
(2):193–199.
15.
BuccellettiFDi SommaSIacominiP. Assessment of baseline characteristics and risk factors among emergency department patients presenting with recent onset atrial fibrillation: a retrospective cohort study. Eur Rev Med Pharmacol Sci. 2013;17
(suppl 1):22–27.
16.
NairAHazellWSuttonTPillaiS. Antithrombotic therapy in atrial fibrillation: An assessment of compliance with guidelines. N Z Med J. 2005;118
(1208):U1258.
17.
CammAJLipGYDe CaterinaR. 2012 focused update of the esc guidelines for the management of atrial fibrillation: an update of the 2010 esc guidelines for the management of atrial fibrillation. Developed with the special contribution of the european heart rhythm association. Eur Heart J. 2012;33
(21):2719–2747.
18.
MantJHobbsFDFletcherK. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the birmingham atrial fibrillation treatment of the aged study, bafta): a randomised controlled trial. Lancet. 2007;370
(9586):493–503.
19.
FribergLRosenqvistMLipGY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The swedish atrial fibrillation cohort study. Eur Heart J. 2012;33
(12):1500–1510.
20.
Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546–554.
21.
EvansAPerezIYuGKalraL. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?Stroke. 2001;32
(12):2828–2832.
22.
TsivgoulisGSpengosKZakopoulosN. Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study. Age Ageing. 2005;34
(1):35–40.
23.
HartRGPearceLAMcBrideRRothbartRMAsingerRW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the spaf i-iii clinical trials. The stroke prevention in atrial fibrillation (spaf) investigators. Stroke. 1999;30
(6):1223–1229.
24.
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154
(13):1449–1457.
25.
Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med. 1998;158
(12):1316–1320.
26.
HaysAGSaccoRLRundekT. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke. 2006;37
(7):1715–1719.
